3 weeks ago
Zydus Lifesciences Q1 profit slides 36% to Rs 940 crore
Zydus Lifesciences is a big medicine-making company in India that has been around since 1952.
It told everyone how much money it made in the first three months of its new business year.
This time, its profit was much smaller than last year's — 940 crore rupees compared with 1,467 crore rupees.
That might sound strange, because the company actually sold more medicines than before, making 8,017 crore rupees in sales.
Profit is the money left over after a company pays all its costs, and Zydus's costs grew faster than its sales.
The amount it kept as operating profit also shrank, from 31.8% of sales to 24.1%.
People who own shares in the company did not seem too worried, and the share price went up a little after the announcement.
Zydus makes regular medicines, vaccines and other health products, and sells them in more than 50 countries.
It also owns popular consumer brands through its Zydus Wellness branch.
So even when a company sells more, it can still earn less profit if its costs rise faster.
Zydus Lifesciences' consolidated net profit fell 35.9% year-on-year to Rs 940 crore in Q1 FY27, compared with Rs 1,467 crore a year ago.
Revenue from operations rose 22% to Rs 8,017 crore, up from Rs 6,574 crore in the corresponding quarter of the previous financial year.
EBITDA slipped 7.6% to Rs 1,930 crore, with the EBITDA margin contracting to 24.1% from 31.8%.
Following the results, shares of Zydus Lifesciences traded at Rs 1,126, up 0.63%, and the stock has gained 23.20% year-to-date.
The Ahmedabad-based drugmaker, formerly known as Cadila Healthcare and rebranded in 2022, operates in more than 50 countries with over 30 manufacturing facilities.
- Who
- Zydus Lifesciences, the Ahmedabad-based pharmaceutical company led by Chairman Pankaj R. Patel.
- What
- Reported a 35.9% year-on-year decline in consolidated net profit to Rs 940 crore for Q1 FY27, even as revenue from operations rose 22% to Rs 8,017 crore.
- Where
- India — the company is headquartered in Ahmedabad and announced results via a stock exchange filing.
- When
- June quarter of the current financial year (Q1 FY27); results announced on Tuesday.
- Why
- Profitability came under pressure as EBITDA fell 7.6% and the EBITDA margin contracted to 24.1% from 31.8% despite higher sales.
Key facts
- Company
- Zydus Lifesciences (formerly Cadila Healthcare)
- Net Profit (Q1 FY27)
- Rs 940 crore, down 35.9% YoY from Rs 1,467 crore
- Revenue from Operations
- Rs 8,017 crore, up 22% YoY from Rs 6,574 crore
- EBITDA
- Rs 1,930 crore, down 7.6% YoY
- EBITDA Margin
- 24.1% vs 31.8% in Q1 FY26
- Share Price After Results
- Rs 1,126, up 0.63%
- Headquarters
- Ahmedabad, India
- Global Presence
- 50+ countries, 30+ manufacturing facilities; consumer brands via Zydus Wellness (Glucon-D, Sugar Free, Complan, Nycil, Everyuth)









